OBJECTIVE—Leukocyte adhesion in retinal microvasculature substantially contributes to diabetic retinopathy. Involvement of the Rho/Rho kinase (ROCK) pathway in diabetic microvasculopathy and therapeutic potential of fasudil, a selective ROCK inhibitor, are investigated.

RESEARCH DESIGN AND METHODS—Localization of RhoA/ROCK and Rho activity were examined in retinal tissues of rats. Impact of intravitreal fasudil administration on retinal endothelial nitric oxide synthase (eNOS) and myosin phosphatase target protein (MYPT)-1 phosphorylation, intercellular adhesion molecule-1 (ICAM-1) expression, leukocyte adhesion, and endothelial damage in rat eyes were investigated. Adhesion of neutrophils from diabetic retinopathy patients or nondiabetic control subjects to cultured microvascular endothelial cells was quantified. The potential of fasudil for endothelial protection was investigated by measuring the number of adherent neutrophils and terminal transferase-mediated dUTP nick-end labeling—positive endothelial cells.

RESULTS—RhoA and ROCK colocalized predominantly in retinal microvessels. Significant Rho activation was observed in retinas of diabetic rats. Intravitreal fasudil significantly increased eNOS phosphorylation, whereas it reduced MYPT-1 phosphorylation, ICAM-1 expression, leukocyte adhesion, and the number of damaged endothelium in retinas of diabetic rats. Neutrophils from diabetic retinopathy patients showed significantly higher adhesion to cultured endothelium and caused endothelial apoptosis, which was significantly reduced by fasudil. Blockade of the Fas-FasL interaction prevented endothelial apoptosis. The protective effect of fasudil on endothelial apoptosis was significantly reversed by Nω-nitro-L-arginine methyl ester, a NOS inhibitor, whereas neutrophil adhesion remained unaffected.

CONCLUSIONS—The Rho/ROCK pathway plays a critical role in diabetic retinal microvasculopathy. Fasudil protects the vascular endothelium by inhibiting neutrophil adhesion and reducing neutrophil-induced endothelial injury. ROCK inhibition may become a new strategy in the management of diabetic retinopathy, especially in its early stages. Diabetes 58:215–226, 2009

Diabetic retinopathy, a prevalent complication of diabetes, is a leading cause of vision loss (1). Early nonproliferative stages of diabetic retinopathy are characterized by retinal microvascular damage that leads to vascular hyperpermeability. Although visual acuity is rarely affected in this early stage, progression of the diseased states leads to proliferative retinopathy that can cause severe vision loss. Vitreous hemorrhage caused by a rupture of neovascular vessels and tractional retinal detachment associated with a cicatrical contraction of proliferative membranes are hallmark of the later diabetic retinopathy stages. Despite considerable recent advances in vitreoretinal surgery, generally performed in later diabetic retinopathy stages, a satisfying visual acuity cannot be always achieved. Even in the early diabetic retinopathy stages that might be detected by routine eye exams, management of general factors, such as blood glucose level (2) and blood pressure (3), currently constitute the only preventive measures. New approaches for amelioration and treatment of diabetic retinopathy, especially in the earlier stages, are thus urgently needed.

The various clinical findings in the retinal vasculature throughout diabetic retinopathy, such as capillary occlusion and leakage, are related to endothelial damage secondary to increased leukocyte adhesion at least in part (4,5). Diabetic leukocyte adhesion in retinal microvessels is mediated by adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1) and leukocyte β2-integrins (CD18/CD11a and CD18/CD11b) (6). In experimental diabetes, the expressions of these molecules are increased, and their blockade prevents leukocyte adhesion and endothelial damage (7). The interaction of endothelial Fas with Fas ligand (FasL), expressed on adherent neutrophils, causes endothelial damage and apoptosis in experimental diabetes (8). However, the role of the Fas/FasL pathway in human diabetic microvasculopathy remains to be investigated.

Rho/Rho kinase (ROCK) pathway plays an important role in pathological vascular conditions, such as cerebral and coronary spasm (9), hypertension (10), and arteriosclerosis (11). Fasudil, a potent and selective ROCK inhibitor, is relatively safe and effective in the treatment of cardiovascular disease (12). Recent studies have shown that the Rho/ROCK pathway is also involved in the pathogenesis of diabetes complications in rat renal cortex (13) and aorta (14). In vitro, Rho activity is increased in bovine aortic endothelial cells treated with high glucose (15). Rho/ROCK pathway promotes leukocyte adhesion to the microvasculature by affecting the expression and function.
of adhesion molecules. For instance, Rho/ROCK activation increases ICAM-1 expression (16). In addition, Rho/ROCK signaling is associated with ICAM-1 clustering (17) and activation of ezrin, radixin, and moesin in endothelial cells, which jointly form the anchoring structures for leukocyte integrins (18,19). Activation of the Rho/ROCK pathway stimulates phosphorylation of myosin regulatory light chain (MLC) (20), causing firm adhesion of leukocytes to the microvasculature by promoting the higher affinity state of integrins (21) and their assembly (22).

Endothelial nitric oxide (NO) synthase (eNOS) generates NO, a potent vasodilator (23) and antiapoptotic factor (24,25). eNOS expression and function through phosphorylation is decreased in diabetic rat aorta (26) and myocardium (27). In vitro, eNOS phosphorylation is also reduced by high glucose in coronary artery endothelial cells (28) or bovine aortic endothelial cells (29). Because Rho/ROCK activation dephosphorylates eNOS in human umbilical venous cells (30), we hypothesize that ROCK inhibition may be antiapoptotic in retinal endothelium during diabetes.

In the present study, we investigate the mechanisms of endothelial damage in diabetic microvasculopathy using neutrophils from diabetic patients. We reveal the critical role of Rho/ROCK pathway in retinal microvascular damage associated with diabetes. Moreover, we examine the potential benefit of fasudil as a therapeutic agent in amelioration and treatment of diabetes-induced microvascular damage especially in the early diabetic retinopathy stages.

RESEARCH DESIGN AND METHODS

Anti-RhoA mouse monoclonal antibody (mAb), anti-ROCK1 (sc-5561), ROCK2 (sc-5651) rabbit polyclonal antibody (pAb), and anti-CD34 mAb were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488–conjugated anti-rabbit pAb and anti-mouse pAb, Alexa Fluor 555–conjugated anti-mouse pAb, and DAPI were obtained from Molecular Probes (Eugene, OR). For flow cytometry, anti-rat mAbs (CD11a, CD11b, CD18, and FasL) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human tumor necrosis factor-α (rhTNF-α) was purchased from Sigma (Tokyo). Fasudil, a potent and selective ROCK inhibitor, was a gift of Asahi Kasei Pharma (Tokyo). ROCK2. After washing, sections were incubated with Alexa Fluor 488–conjugated secondary antibody. For double staining, anti-CD34 mAb and Alexa Fluor 555–conjugated secondary antibody were used for staining endothelial cells. Counterstaining of nuclei was performed with DAPI. Stain-
necrotic cells (green fluorescence) were detected by terminal transferase-mediated dUTP nick-end labeling (TUNEL) staining with the TdT fluorescein in situ apoptosis detection kit (R&D Systems), according to the manufacturer’s protocol. Apoptotic HMVECs demonstrated double labeling and appeared yellow. The number of apoptotic cells in four different areas per well was counted using fluorescence microscopy.

To determine the involvement of NO and Fas/FasL signaling in endothelial apoptosis, HMVECs were preincubated with 1 mmol/l 35 mmol/l-Nω-nitro-L-arginine methyl ester (L-NAME; Sigma), an inhibitor of NOS, before fasudil treatment, and neutrophils were incubated with soluble Fas receptor (sFasR; Kamiya Biomedical, Seattle, WA), which inhibits FasL-induced apoptosis by acting as a decoy receptor, before coculture for 1 h at 37°C. To investigate the involvement of Rho/ROCK pathway in Fas/FasL signaling, HMVECs were preincubated with fasudil in the presence or absence of L-NAME before the addition of soluble FasL (Sigma) for 1 h at 37°C.

Statistical analysis. All results were expressed as means ± SE. Statistical differences were assessed using the nonparametric Kruskal-Wallis variance analysis. To adjust for inflated α errors due to multiple comparisons, the corrected significant P value was defined using the Bonferroni correction. Statistical differences between two groups were analyzed by Mann-Whitney U test.

RESULTS

Rho/ROCK activation in retinal vessels during diabetes. To investigate the localization of RhoA, ROCK1, and ROCK2, we harvested rat retinal tissue and performed immunohistochemistry. These proteins were mainly expressed in retinal vessels, because endothelial and vascular smooth muscle cells exhibited positive staining (Fig. 1A–C).

In addition, the levels of activated Rho (p-GTP) were significantly higher in the diabetic rat retinas, compared with those in nondiabetic controls (1.31-fold, P < 0.01, n = 5 each) (Fig. 1D and E).

ROCK suppression in the retina by fasudil. Two weeks after diabetes onset, diabetic rats showed significant weight loss compared with the nondiabetic controls (non-diabetic [n = 15], 346 ± 21 g vs. diabetic [n = 15], 253 ± 15 g, P < 0.01). Fasudil treatment did not affect the diabetic weight loss (n = 15, 266 ± 6 g, NS). The average blood glucose levels (446 ± 13 mg/dl) in diabetic rats were significantly higher compared with those of nondiabetic rats (127 ± 21 mg/dl, P < 0.01), and fasudil treatment did not affect diabetic rat blood glucose levels (460 ± 26 mg/dl).

To examine the efficacy of fasudil for ROCK inhibition in the retina, we quantified the amount of phosphorylated MYPT-1 and eNOS, downstream targets of ROCK. In line with our Rho activity data (Fig. 1D and E), MYPT-1 phosphorylation was markedly increased in the retinas of vehicle-treated diabetic rats, compared with the vehicle-treated nondiabetic controls (2.7-fold, n = 6 each, P < 0.01). In comparison, treatment with fasudil in diabetic rats significantly reduced the increase of phosphorylated MYPT-1 by 67% (n = 6 each, P < 0.01) (Fig. 2B).

In addition, eNOS and eNOS phosphorylation in the retinas of vehicle-treated diabetic rats were downregulated by 35 and 57%, respectively, compared with vehicle-treated nondiabetic controls (n = 6 each, P < 0.01). Fasudil treatment almost completely reversed the decreased eNOS expression and phosphorylation in diabetic rat retinas (n = 6 each, P < 0.01; Fig. 2C and D).
neutrophils were significantly higher than those of normal controls (135 ± 0.01, and 176 ± 0.01, respectively, n = 8 each). However, the mean fluorescence intensity of CD11a in neutrophils of diabetic animals (1,170 ± 161) did not differ significantly from that of normal controls (1,049 ± 63, n = 8 each, NS) (Fig. 3A–F).

Furthermore, in diabetic retinas, ICAM-1 expression was significantly elevated compared with nondiabetic controls (1.21-fold, P < 0.01, n = 7 each; Fig. 3G). The number of firmly adhering leukocytes in retinas of the diabetic animals was 3.8-fold higher than in the nondiabetic controls (n = 7 each, P<0.01; Fig. 3H and I). ROCK inhibition by intravitreal fasudil injection significantly reduced ICAM-1 expressions in the diabetic retinas by 83% of the increase in vehicle-treated diabetic controls compared with the vehicle-treated nondiabetic controls (n = 7 each, P < 0.01; Fig. 3G). Furthermore, the diabetes-induced leukocyte adhesion to retinal vasculature was significantly suppressed by 68% in fasudil-treated animals (n = 7 each, P < 0.01; Fig. 3H and I). Leukocyte adhesion in vehicle-treated rats did not significantly differ from that in untreated control rats (n = 7 each; Fig. 3H and I). Integrin expressions in fasudil-treated diabetic animals did not significantly differ from those of vehicle-treated diabetic rats (n = 7 each; Fig. 3A–F).

Prevention of neutrophil-induced retinal endothelial damage in diabetic animals by fasudil. The expression of FasL, an apoptosis-inducing factor, on the surface of the peripheral blood neutrophils from diabetic animals (553 ± 47, n = 8) was significantly higher compared with that from nondiabetic controls (553 ± 47, n = 8, P < 0.01). Intravitreal injection of fasudil did not significantly change the expressions of FasL on peripheral blood neutrophils (Fig. 4A and B).

In vivo, the number of propidium iodide–positive injured or dead endothelial cells per retina was significantly increased by 8.1-fold in diabetic rats compared with the nondiabetic controls (n = 5 each, P < 0.01). In the fasudil-treated diabetic animals, the number of propidium iodide–positive cells in the retina showed a significant 94% reduction of the increase in the vehicle-treated diabetic controls (P < 0.01), whereas the number of propidium iodide–positive cells in vehicle-treated rats did not signif-

---

**FIG. 2. Impact of intravitreal fasudil on retinal ROCK activity.** Phosphorylated MYPT-1 (Thr853) and eNOS (Ser1177) were detected in rat retinal preparations by Western blot analysis. Lane loading differences were normalized by reblotting the membranes with an antibody against GAPDH. A: Representative results of phospho-MYPT-1 and GAPDH in rat retinas. B: ROCK activity was expressed as the ratio of phospho-MYPT-1 to GAPDH (**P < 0.01, NS; n = 6 each). C: Representative results of phospho-eNOS and GAPDH. D: Average signal intensities quantified and expressed as percentage of the ratio of control (**P < 0.05, NS; n = 6 each).
**FIG. 3.** Reduction of diabetes-induced retinal leukocyte adhesion by fasudil. Intravitreal injections of fasudil at 0 μmol/l (vehicle) or 30 μmol/l (final vitreal concentration) were performed every 3 days for 2 weeks. Cell surface expressions of CD11a (A), CD11b (C), and CD18 (E) on nondiabetic control (thin line) and diabetic rat neutrophils (thick line) were analyzed by flow cytometry. Mean fluorescence intensity of CD11a (B), CD11b (D), and CD18 (F) (**P < 0.01, NS; n = 8 each; dotted line, mouse isotype control). G: Retinal ICAM-1 concentrations measured by enzyme-linked immunosorbent assay in retinas of normal and diabetic animals with and without fasudil treatment (**P < 0.01, n = 7 each). H: Representative ConA-stained flat mounts of normal and diabetic animals with and without fasudil treatment (**P < 0.01, NS; n = 7 each). (Please see http://dx.doi.org/10.2337/db08-0762 for a high-quality digital representation of this figure.)

**Reduced adhesion of human diabetic neutrophils to HMVECs by fasudil.** The mean fluorescence of CD18 (69 ± 11, P < 0.05 vs. control) and CD11b (266 ± 60, P < 0.05 vs. control) in neutrophils of diabetic retinopathy patients was significantly higher than in nondiabetic controls (CD18 [45 ± 9] and CD11b [118 ± 31], respectively). CD11a expression in neutrophils of diabetic retinopathy patients (363 ± 58) did not significantly
differ from that of the nondiabetic control subjects (405 ± 50) (n = 20 each, Fig. 5A–F).

The number of diabetic retinopathy neutrophils that bound to HMVECs was 1.9-fold higher than that of the nondiabetic controls (n = 15, P<0.01). Fasudil significantly reduced diabetic retinopathy patients’ neutrophil adhesion in a dose-dependent manner (38% reduction at 5 μmol/l, P < 0.01; 63% reduction at 20 μmol/l, n = 15 each, P < 0.01). However, the adhesion of peripheral blood neutrophils from nondiabetic controls was not significantly affected with fasudil treatment (20 μmol/l: 45% reduction, n = 15, vs. without fasudil; Fig. 5G and H).

**Role of Fas/FasL in neutrophil-induced endothelial apoptosis.** To elucidate mechanisms of immune cell-mediated vascular injury during diabetes, we measured the expression of FasL on the surface of peripheral blood neutrophils from diabetic retinopathy patients and nondiabetic controls by flow cytometry. The mean fluorescence of FasL (8.6 ± 1.6) on diabetic retinopathy neutrophils was significantly higher than that of nondiabetic controls (4.2 ± 0.5, n = 17 each, P < 0.01) (Fig. 6A and B).

Endothelial apoptosis, induced by diabetic retinopathy neutrophils, was significantly inhibited by sFasR, which
competitively blocks the Fas interaction with FasL, in a dose-dependent manner up to 10 μg/ml (n = 5 each, P < 0.01; Fig. 6C and D).

**Prevention of sFasL or neutrophil-induced endothelial apoptosis by fasudil.** HMVEC incubation with control or diabetic retinopathy neutrophils significantly
increased the number of TUNEL-positive apoptotic cells (control neutrophils, 9.8 ± 2.7 cells/mm², n = 15, P < 0.01; diabetic retinopathy neutrophils, 33.2 ± 8.0 cells/mm², n = 15, *P < 0.01 vs. no neutrophils, respectively; Fig. 7A and B). Treatment of the diabetic retinopathy neutrophils with fasudil significantly decreased endothelial apoptosis in a dose-dependent fashion (diabetic retinopathy neutrophils with fasudil at 5 μmol/l, 17.9 ± 6.9 cells/mm², *P < 0.01 or at 20 μmol/l, 6.1 ± 1.4 cells/mm², *P < 0.01 vs. without fasudil, respectively, n = 15 each; Fig. 7A and B).

Incubation of HMVECs with sFasL significantly increased the number of endothelial apoptosis (with sFasL, 24.8 ± 6.1 cells/mm², *P < 0.01 vs. vehicle, 5.3 ± 0.8...
cells/mm²), which was significantly reduced by fasudil treatment (sFasL with fasudil, 6.0 ± 2.2 cells/mm², *P < 0.01 vs. sFasL alone, *n = 4 each; Fig. 7C and D).

**Protective role of NO in neutrophil-induced endothelial apoptosis.** L-NAME, a broad inhibitor of NOSs, significantly reversed the effect of fasudil on sFasL-induced apoptosis.

**FIG. 7.** Prevention of neutrophil-induced endothelial apoptosis by fasudil. A and B: After pretreatment with 0, 5, or 20 μmol/l fasudil for 1 h, HMVECs were stimulated for 12 h with 10 ng/ml rhTNF-α. Subsequently, unlabeled neutrophils (5 × 10⁵ cells/ml) were cocultured with HMVECs for 12 h. Scale bar = 100 μm. The number of apoptotic cells (yellow fluorescence) in four different areas per well was counted (**P < 0.01, NS; *n = 15 each). C and D: Involvement of fasudil in sFasL-induced apoptosis was investigated. HMVECs were preincubated with or without 20 μmol/l fasudil before sFasL treatment for 1 h. Furthermore, HMVECs were incubated with or without 1 mmol/l L-NAME before fasudil treatment for 1 h. Scale bar = 100 μm. The number of TUNEL-positive cells in four different areas per well was counted and averaged (**P < 0.01, NS; *n = 4 each). (Please see http://dx.doi.org/10.2337/db08-0762 for a high-quality digital representation of this figure.)
endothelial apoptosis ($P < 0.01, n = 4$ each; Fig. 7C and D). L-NAME did not affect the fasudil-induced decrease in the number of patient neutrophil binding to the endothelial cells compared with diabetic retinopathy neutrophils without L-NAME ($n = 10$ each, NS; Fig. 8A). However, the protective effect of fasudil on endothelial apoptosis was significantly reversed by L-NAME compared with diabetic retinopathy neutrophils without L-NAME ($n = 10$ each, $P < 0.01$; Fig. 8B).

**DISCUSSION**

The rapidly growing prevalence of diabetes necessitates the development of new therapeutic strategies for diabetic retinopathy, a blinding complication of the disease. This work introduces the role of Rho/ROCK pathway in the diabetic retinal microvascular damage. We demonstrate the therapeutic potential of fasudil, a potent and selective ROCK inhibitor, as a novel pharmacological strategy in early diabetic retinopathy treatment.

Our results show colocalization of RhoA and ROCK predominantly in retinal microvessels. We found enhanced levels of p-GTP and phosphorylated MYPT-1, a downstream mediator of ROCK, in retinas of diabetic rats, demonstrating the activation of the Rho/ROCK pathway in retinal microvessels during diabetes. These findings suggest involvement and elevated activity of the Rho/ROCK pathway in the pathogenesis of diabetic microvascularopathy. We thus investigated whether the inhibition of this pathway might be beneficial in amelioration or treatment of diabetic microvascular damage.

Fasudil is a selective ROCK inhibitor with minimal effects on other pathways, such as MLC kinase or protein kinase C (35). Our recent experiments have confirmed that repeated intravitreal injections of fasudil at a final concentration of 30 μmol/l in rabbit eyes and single intravitreal injection of fasudil up to 100 μmol/l in rat eyes did not cause apparent electrophysiological or morphological changes in retinal tissues or induction of inflammatory cells, compared with the untreated control eyes (36).

Intravitreal injection of vehicle also did not cause significant leukocyte adhesion or endothelial damage in rat retinas, compared with untreated control. We demonstrated its efficacy for retinal ROCK inhibition after intravitreal injection, measured by MYPT-1 phosphorylation.

Our investigations of the impact of fasudil on diabetic leukocyte adhesion showed, in line with previous reports, elevated retinal ICAM-1 (34,37) and increased CD18/CD11b expression on peripheral blood neutrophils (7) of the diabetic animals. These findings indicate higher adhesive properties of both neutrophils and the vascular endothelium during diabetes. We further provide evidence that intravitreal injection of fasudil effectively suppresses the increased ICAM-1 expression and retinal leukocyte adhesion in diabetic animals. However, it appears that the dramatic effect of fasudil in reducing diabetic leukocyte adhesion may be not solely explained by the reduction of ICAM-1 expression. In addition to ICAM-1 expression, it is possible that fasudil may affect ICAM-1 clustering and assembly, because clustering (17) and assembly (18,19) of ICAM-1 at focal adhesion sites are critical for the molecule’s affinity. Fasudil also dilates retinal vessels and increases blood flow (10). Therefore, it is feasible that the reduction of the retinal leukocyte adhesion in fasudil-treated diabetic animals could be in part due to improved hemodynamics in the retinal vessels.

Our experiments furthermore confirmed that the endothelial damage in retinas of diabetic animals is widely associated with leukocyte adhesion. In line with previous reports, we found elevated FasL expression on peripheral blood neutrophils in diabetic rats (8), suggesting that...
firmly adhering leukocytes may induce endothelial damage during diabetes via Fas/FasL signaling. Moreover, fasudil effectively suppressed endothelial damage, even when leukocytes firmly adhered to the endothelium. As a possible mechanism, in addition to attenuating retinal leukocyte adhesion, the restored eNOS phosphorylation in rat retina by fasudil might contribute to the prevention of leukocyte-induced endothelial damage.

To further elucidate the mechanisms of leukocyte-induced endothelial damage and protective effect of fasudil, we investigated the adhesion and proapoptotic effects of human neutrophils from normal subjects and diabetic retinopathy patients on the microvascular endothelium in vitro.

Similar to diabetic rats, the expressions of adhesion molecules on neutrophils from diabetic retinopathy patients were remarkably increased, compared with nondiabetic control subjects. In this study, we used TNF-α to enhance neutrophil adhesion and neutrophil-induced endothelial apoptosis in the diabetic coculture assay, because TNF-α has been implicated in the pathogenesis of diabetic microvascular damage (38–40) and diabetic retinopathy (40,41).

Compared with nondiabetic neutrophils, diabetic retinopathy neutrophils adhere significantly more to the cultured endothelium, which is effectively suppressed by fasudil treatment. Without neutrophils, only few endothelial cells were found apoptotic. In comparison, neutrophils from diabetic retinopathy patients caused significantly higher numbers of apoptosis in the endothelium, which was effectively inhibited by fasudil treatment. Furthermore, diabetic retinopathy neutrophil-induced endothelial apoptosis was significantly reduced by competitive inhibition of FasL with sFasR, indicating the critical role of endothelial Fas interaction with FasL on adherent neutrophils for apoptosis. This may in part contribute to the pathogenesis of diabetic microvasculopathy.

The fact that fasudil inhibits neutrophil-induced endothelial apoptosis and sFasL-induced endothelial apoptosis suggests that the vasculoprotective function of fasudil may be in part due to inhibition of Fas/FasL signaling, activated by adherent neutrophils. Our results further suggest that the protective effect of fasudil on endothelial apoptosis is likely NO mediated, because it was significantly blocked by NOS inhibition with L-NAME, without apparent effect on neutrophil adhesion. This suggests that fasudil may cause direct NO-mediated endothelial protection that is independent of its impact on neutrophil adhesion. Moreover, we demonstrate that L-NAME reverses sFasL-induced endothelial apoptosis. These observations indicate that fasudil protects from Fas/FasL-induced endothelial damage, a process that appears to be NO dependent. In contrast, previous reports indicate that inducible NO synthase (iNOS) is involved in leukostasis and vascular abnormality in STZ mice (42,43). NO can prevent or promote apoptosis in endothelial cells, dependent on its concentration and source. Physiological levels of NO, synthesized by eNOS, contribute to endothelial protection (44,45), whereas excessive levels of NO, synthesized by overexpression of iNOS, promote destruction of endothelial cells (46). In the retinas of our experimentally diabetic rats, iNOS expression was not significantly changed with or without fasudil treatment (data not shown). A further complication is that in vitro and in vivo eNOS expression in response to high glucose is highly time dependent, initially increasing (47), but eventually declining (26,48–50). Our study was performed when eNOS expression in retinas of diabetic rats was expected to be lower than baseline levels.

Because the course of retinal changes during diabetes in rats may differ from that in humans, further studies will be needed to assess the therapeutic potential and safety of fasudil in diabetic retinopathy patients. Our data reveal the critical role of the Rho/ROCK pathway in the pathogenesis of diabetic retinal microvasculopathy and the therapeutic potential of the ROCK inhibitor, fasudil, in reducing diabetic retinal leukocyte accumulation and endothelial damage. ROCK inhibition might become a novel therapeutic strategy in the treatment of diabetic retinopathy, especially in its earlier stages.

ACKNOWLEDGMENTS
S.N. has received a Research Fellowship Award from Bausch & Lomb and a Fellowship Award from the Japan Eye Bank Association. This study has received Grant-in-Aid for Scientific Research 19592026 from the Ministry of Education, Science, Sports and Culture, Japan; National Institutes of Health Grants AI050775 and HL086933; National Eye Institute Core Grant EY14104; and support from the Massachusetts Lions Eye Research Fund, the Marion W. and Edward F. Knight Fund, and Research to Prevent Blindness.

No potential conflicts of interest relevant to this article were reported.

We thank Asahi Kasei Pharma for the gift of fasudil. We also thank Yusuke Murakami, Ri-ichiro Kohno, and Takeru Yoshimura (Department of Ophthalmology, Kyushu University) for their technical support. We appreciate the technical support from the Research Support Center, Graduate School of Medical Sciences, Kyushu University.

REFERENCES
1. Pastor JC, de la Rua ER, Martin F: Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21:127–144, 2002
2. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998
3. U.K. Prospective Diabetes Study (UKPDS) Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 30). BMJ 317:713–720, 1998
4. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adams AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147–152, 2001
5. Schroder S, Palinski W, Schmid-Schonbein GW: Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81–100, 1991
6. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC: Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 83:2008–2017, 1989
7. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscnikas EW, Adamsen AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41:1153–1158, 2000
8. Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook RS, Epper P, Mitsiades CS, Kirchhof B, Adamsen AP, Aiello LP: Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FEBS J 17:76–78, 2003
9. Masamoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545– 1547, 2002
10. Okamura N, Saito M, Mori A, Sakamoto K, Kametaka S, Nakahara T, Ishii K: Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arte-
FASUDIL AMELIORATES DIABETIC MICROVASCULOPATHY

rioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther 23:207–212, 2007
11. Miyata K, Shimoakawa H, Kandabashi T, Higo T, Morishige K, Eto Y, Egashira K, Kabiuchi K, Takeshita A: Rho-kinase is involved in macrophage-activation-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20:2351–2358, 2000
12. Shimokawa H, Rashid M: Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28:296–302, 2007
13. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR: Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57:714–723, 2008
14. Tang J, Kusaka I, Massey AR, Rollins S, Zhang JH: Increased RhoA translocation in aorta of diabetic rats. Acta Pharmacol Sin 27:543–548, 2006
15. Iwasaki H, Okamoto R, Kato S, Konishi K, Mizutani H, Yamada N, Isaka N, Nakano T, Ito M: High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-κB activation in bovine aortic endothelial cells. Atherosclerosis 196:22–28, 2008
16. Lee H, Lin CJ, Liao JJ, Lee YW, Yang HY, Lee CY, Wu HL: Lysophospholipids increase ICAM-1 expression in HUVEC in HIVEC through a Gi- and NF-κB-dependent mechanism. Am J Physiol Cell Physiol 287:C1657–C1666, 2004
17. Wojcik-Stothard B, Williams L, Ridley AJ: Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-activated receptor kinase. J Cell Biol 145:1293–1307, 1999
18. Barreiro O, Yanese-Mo S, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, Furthmayr H, Sanchez-Madrid F: Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 157:1233–1245, 2002
19. Mackay DJ, Esch F, Furthmayr H, Hall A: Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts is an essential role for ezrin/radixin/moesin proteins. J Biol Chem 270:927–938, 1995
20. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori Y, Egashira K, Kaibuchi K, Takeshita A: Rho-kinase is involved in macrophage and NF-kappaB-dependent mechanism. Circulation 105:17504–17509, 2007
21. Miyamoto K, Khosros S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adams AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836–10841, 1999
22. Guo X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, Capobianco S, Chillan WM, Zhang C: Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 115:245–254, 2007
23. Ciszar A, Ungvari ZI: Endothelial dysfunction and vascular inflammation in type II diabetes: interaction of AGE/RAGE and TNF[alpha] signaling. Am J Heart Circ Physiol 295:H147–H148, 2007
24. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT: Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 172:1411–1418, 2008
25. Jousen AM, Pouliak V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adams AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438–440, 2002
26. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV: Inducible nitric oxide synthase isoform is a key mediator of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105:17504–17509, 2008
27. Miyamoto K, Khosros S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adams AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836–10841, 1999. 
28. Rhee SW, Kim SJ, Shin YK, Na SY, Cho SH, Jang KB: N(omega)-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartate-induced neurotoxicity in vivo. Eur J Pharmacol 328:45–49, 1997
29. Nakamura RE, Hunter DD, Yi H, Brunken WJ, Hackman AS: Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol 8:52, 2007
30. English D, Andersen BR: Single-step separation of red blood cells: granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5:249–252, 1974
31. Miyahara S, Kiyu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, Ezhala H, Goto Y, Shimoaka H, Hafezi-Moghadam A, Ishibashi T: Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105:17504–17509, 2008
32. Miyamoto K, Khosros S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adams AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836–10841, 1999
33. Ciszar A, Ungvari ZI: Endothelial dysfunction and vascular inflammation in type II diabetes: interaction of AGE/RAGE and TNF[alpha] signaling. Am J Heart Circ Physiol 295:H147–H148, 2007
34. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT: Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 172:1411–1418, 2008
35. Jousen AM, Pouliak V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adams AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438–440, 2002
36. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV: Inducible nitric oxide synthase isoform is a key mediator of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105:17504–17509, 2008
37. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, Kern TS: Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50:1987–1996, 2007
38. Hafezi-Moghadam A, Simoncini T, Yang Z, Limburg FP, Plummer JC, Bekbus MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK: Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8:473–479, 2002
39. Prorock AJ, Hafezi-Moghadam A, Laubach VE, Liao JK, Ley K: Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am J Heart Circ Physiol 284:H130–H140, 2007
40. Shen YH, Wang XL, Wilcken DE: Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett 433:125–131, 1998
41. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, Hedrick CC: Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 47:1727–1734, 2004
42. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47:945–952, 1998
43. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM: Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Heart Circ Physiol 280:H2144–H2152, 2012
44. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwell RW: Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319:386–395, 2006
50. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwell RW: Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319:386–395, 2006.